An open-label, multicenter, extension study to evaluate the safety and tolerability of natalizumab following re-initiation of dosing in multiple sclerosis subjects who have completed study C-1801, C-1802, or C-1803 and a dosing suspension safety evaluation.

Trial Profile

An open-label, multicenter, extension study to evaluate the safety and tolerability of natalizumab following re-initiation of dosing in multiple sclerosis subjects who have completed study C-1801, C-1802, or C-1803 and a dosing suspension safety evaluation.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biogen Idec
  • Most Recent Events

    • 02 Feb 2010 Actual number of patients (404) added as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top